Review
Nature Reviews Cancer 6, 38-51 (January 2006) | doi:10.1038/nrc1779
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Saverio Minucci1,2 About the author & Pier Giuseppe Pelicci1,3
Abstract
Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clinical trials. A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved. However, several basic aspects are not yet fully understood. Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clinical protocols.
- View At a Glance
Author affiliations
- Department of Experimental Oncology, European Institute of Oncology, Via Ripamanti 435, 20141, Milan, Italy.
- Department of Biomolecular sciences and Biotechnology, University of Milan, Milan 20100, Italy.
- Department of Medicine, University of Milan, Milan 20100, Italy.
Correspondence to: Saverio Minucci1,2 Email: saverio.minucci@ifom-ieo-campus.it
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
